Septerna Common Stock (SEPN) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Description:

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

19 Nov '24 Wells Fargo
Overweight
19 Nov '24 TD Cowen
Buy
19 Nov '24 JP Morgan
Overweight
19 Nov '24 Cantor Fitzgerald
Overweight

Screeners with SEPN included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
SEPN
globenewswire.com30 October 2024

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna.

FAQ

  • What is the primary business of Septerna Common Stock?
  • What is the ticker symbol for Septerna Common Stock?
  • Does Septerna Common Stock pay dividends?
  • What sector is Septerna Common Stock in?
  • What industry is Septerna Common Stock in?
  • What country is Septerna Common Stock based in?
  • Is Septerna Common Stock in the S&P 500?
  • Is Septerna Common Stock in the NASDAQ 100?
  • Is Septerna Common Stock in the Dow Jones?
  • When does Septerna Common Stock report earnings?
  • Should I buy Septerna Common Stock stock now?

What is the primary business of Septerna Common Stock?

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

What is the ticker symbol for Septerna Common Stock?

The ticker symbol for Septerna Common Stock is NASDAQ:SEPN

Does Septerna Common Stock pay dividends?

No, Septerna Common Stock does not pay dividends

What sector is Septerna Common Stock in?

Septerna Common Stock is in the Healthcare sector

What industry is Septerna Common Stock in?

Septerna Common Stock is in the Biotechnology industry

What country is Septerna Common Stock based in?

Septerna Common Stock is headquartered in United States

Is Septerna Common Stock in the S&P 500?

No, Septerna Common Stock is not included in the S&P 500 index

Is Septerna Common Stock in the NASDAQ 100?

No, Septerna Common Stock is not included in the NASDAQ 100 index

Is Septerna Common Stock in the Dow Jones?

No, Septerna Common Stock is not included in the Dow Jones index

When does Septerna Common Stock report earnings?

The date for Septerna Common Stock's next earnings report has not been announced yet

Should I buy Septerna Common Stock stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions